KRBPQ — Kiromic Biopharma Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $12.52m
Annual income statement for Kiromic Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.2 | 25.6 | 34.6 | 21.7 | 23.8 |
| Operating Profit | -19.2 | -25.6 | -34.6 | -21.7 | -23.8 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.2 | -25.6 | -34.7 | -20.9 | -26.9 |
| Net Income After Taxes | -19.2 | -25.6 | -34.7 | -20.9 | -26.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.2 | -25.6 | -34.7 | -20.9 | -26.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.9 | -25.8 | -35.1 | -23.5 | -33.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -81.6 | -67 | -58.1 | -19.8 | -23.1 |